$35.9
AnaptysBio is a biotechnology business based in the US. AnaptysBio shares (ANAB) are listed on the NASDAQ and all prices are listed in US Dollars. AnaptysBio employs 117 staff and has a trailing 12-month revenue of around $30.5 million.
Our top picks for where to buy AnaptysBio stock
How to buy AnaptysBio stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ANAB. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy AnaptysBio stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
AnaptysBio stock price (NASDAQ: ANAB)
Use our graph to track the performance of ANAB stocks over time.AnaptysBio shares at a glance
Latest market close | $35.90 |
---|---|
52-week range | $13.36 - $41.31 |
50-day moving average | $32.24 |
200-day moving average | $24.61 |
Wall St. target price | $52.20 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-6.35 |
Is it a good time to buy AnaptysBio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AnaptysBio price performance over time
Historical closes compared with the close of $35.9 from 2024-09-06
1 week (2024-08-30) | -5.75% |
---|---|
1 month (2024-08-07) | 13.82% |
3 months (2024-06-07) | 53.22% |
6 months (2024-03-07) | 45.76% |
1 year (2023-09-07) | 79.32% |
---|---|
2 years (2022-09-07) | 35.93% |
3 years (2021-09-07) | 38.93% |
5 years (2019-09-06) | 41.1 |
AnaptysBio financials
Revenue TTM | $30.5 million |
---|---|
Gross profit TTM | $-78,511,000 |
Return on assets TTM | -20.52% |
Return on equity TTM | -214.89% |
Profit margin | 0% |
Book value | $0.36 |
Market Capitalization | $1.2 billion |
TTM: trailing 12 months
AnaptysBio share dividends
We're not expecting AnaptysBio to pay a dividend over the next 12 months.
AnaptysBio share price volatility
Over the last 12 months, AnaptysBio's shares have ranged in value from as little as $13.36 up to $41.3083. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AnaptysBio's is -0.241. This would suggest that AnaptysBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, AnaptysBio has bucked the trend.
AnaptysBio overview
AnaptysBio, Inc. , a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc.
Frequently asked questions
nullWhat percentage of AnaptysBio is owned by insiders or institutions?
Currently 1.753% of AnaptysBio shares are held by insiders and 100.438% by institutions. How many people work for AnaptysBio?
Latest data suggests 117 work at AnaptysBio. When does the fiscal year end for AnaptysBio?
AnaptysBio's fiscal year ends in December. Where is AnaptysBio based?
AnaptysBio's address is: 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801 What is AnaptysBio's ISIN number?
AnaptysBio's international securities identification number is: US0327241065 What is AnaptysBio's CUSIP number?
AnaptysBio's Committee on Uniform Securities Identification Procedures number is: 032724106
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question